Abstract
Rheumtatoid arthritis (RA) is a crippling, autoimmune disease, and is characterized by inflammation and destruction of joint tissue. Interleukin-1 (IL-1) has been identified as a key pro-inflammatory cytokine responsible for inflammation. One of the mechanisms of regulation of activity of IL-1 is IL-1 receptor antagonist (IL-1ra)-mediated: IL-1RA competes with IL-1 for binding to the IL-1 receptor. Significant progress has been made in the potential application of IL-1ra gene therapyfor the treatment of arthritis. Various vectors have been tested for the delivery of the IL-1ra gene to the intra-articular region. Recent studies in humans have provided encouraging prospects for IL-1ra-mediated arthritis gene therapy.
MeSH terms
-
Animals
-
Arthritis, Experimental / therapy
-
Arthritis, Rheumatoid / genetics
-
Arthritis, Rheumatoid / therapy*
-
Autoimmune Diseases / genetics
-
Autoimmune Diseases / therapy*
-
Cell Line, Transformed / metabolism
-
Cell Line, Transformed / transplantation
-
Clinical Trials as Topic
-
DNA, Recombinant / administration & dosage
-
DNA, Recombinant / genetics
-
DNA, Recombinant / therapeutic use
-
Dogs
-
Genes, Reporter
-
Genetic Therapy*
-
Genetic Vectors / administration & dosage
-
Genetic Vectors / genetics
-
Genetic Vectors / therapeutic use*
-
Humans
-
Injections, Intra-Articular
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-1 / physiology
-
Mice
-
Rabbits
-
Rats
-
Recombinant Fusion Proteins / physiology
-
Retroviridae / genetics
-
Sialoglycoproteins / genetics*
-
Sialoglycoproteins / physiology
-
Simplexvirus / genetics
-
Synovial Membrane / pathology
-
Transplantation, Autologous
-
Treatment Outcome
Substances
-
DNA, Recombinant
-
IL1RN protein, human
-
Il1rn protein, mouse
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-1
-
Recombinant Fusion Proteins
-
Sialoglycoproteins